Trials in AF and acute coronary syndrome were stopped early for futility, but there’s hope for factor XIa inhibitors given ...
Novel agent abelacimab has potential to be a safer anticoagulant, according to the randomized AZALEA-TIMI 71 trial. The trial had been stopped early because of a surprisingly large reduction in bleeds ...
A pair of Regeneron’s monoclonal antibodies have held their own against a commonly used anticoagulant in a phase 2 trial, with one of the candidates also matching Bristol Myers Squibb and Pfizer’s ...
Anticoagulant treatments are crucial for managing many conditions, such as heart disease, stroke and venous thrombosis. Current options, however, carry an inherent risk of serious bleeding due to ...
Share on Pinterest Can researchers develop, a unique, safer anticoagulant with a significantly lower risk of bleeding? Image credit: Tony Anderson/GettyImages. Anticoagulants are a helpful group of ...
Global Heparin Market OverviewThe global heparin market is projected to expand at a steady compound annual growth rate of around 5% through 2031, supported by the rising burden of chronic and ...
If you’re experiencing severe side effects from the blood thinner warfarin, a doctor may recommend an alternative known as non-vitamin K oral anticoagulants (NOACs). Non-vitamin K oral anticoagulants ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results